Publications by authors named "Francisco Pasquau Liano"
Experience With the Use of Baricitinib and Tocilizumab Monotherapy or Combined, in Patients With Interstitial Pneumonia Secondary to Coronavirus COVID19: A Real-World Study.
José Rosas Francisco Pasquau Liaño Mónica Llombart Cantó José María Carrasco Barea Amparo Raga Beser
Reumatol Clin (Engl Ed)
March 2022
Objective: To describe the experience of treatment with baricitinib (BARI) and/or tocilizumab (TCZ), in monotherapy or combined, in patients admitted for interstitial pneumonia secondary to COVID19, and for 30 days after discharge.
Methods: Medical records of patients admitted with COVID19 and IP with PaO/FiO<300, treated with BARI and/or TCZ, and compared with patients who did not, were retrospectively reviewed.
Results: Sixty patients were included; 43 (72%) are males, mean age 67 (SD: 14) years (<50 years: 17%; 51-70: 30%; >70: 53%), with 8.
Experience With the Use of Baricitinib and Tocilizumab Monotherapy or Combined, in Patients With Interstitial Pneumonia Secondary to Coronavirus COVID19: A Real-World Study.
José Rosas Francisco Pasquau Liaño Mónica Llombart Cantó José María Carrasco Barea Amparo Raga Beser
Reumatol Clin (Engl Ed)
November 2020
Article Synopsis
- The study aimed to analyze the effects of baricitinib (BARI) and tocilizumab (TCZ) treatments on patients hospitalized with COVID-19-related interstitial pneumonia, focusing on their outcomes 30 days post-discharge.
- A total of 60 patients were reviewed, with findings indicating that those treated with BARI had lower ICU admission rates and fewer deaths compared to those treated with TCZ, suggesting varying effectiveness between treatments.
- The researchers concluded that BARI and TCZ are safe options for treating COVID-19-related issues, potentially beneficial for patients with severe cases indicated by low oxygenation levels.
Comparison of the Birmingham Vasculitis Activity Score and the Five-Factor Score to Assess Survival in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Study of 550 Patients From Spain (REVAS Registry).
Roser Solans-Laqué Monica Rodriguez-Carballeira Juan Jose Rios-Blanco Guadalupe Fraile Luis Sáez-Comet
Arthritis Care Res (Hoboken)
July 2020
Article Synopsis
- * Methods: Data from 550 patients diagnosed with AAV were analyzed using ROC curves and multivariable Cox analysis to determine the relationship between the scoring systems and patient outcomes.
- * Results: The study found a significant correlation between higher scores on BVAS and both versions of FFS with increased mortality rates, with the 2009 FFS showing the strongest predictive value for survival compared to the other scores.